TP53 and prostate carcinoma: Immunoblot assays revealed that CAPE treatments downregulated MALT1, PSA, and AR expressions and upregulated p53 and NDRG1 expressions in prostate carcinoma LNCaP cells (Figure 1A and Figure S1).